WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2003000847) MEMBRANE ASSOCIATED PROGESTERONE RECEPTOR
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2003/000847    International Application No.:    PCT/US2002/019545
Publication Date: 03.01.2003 International Filing Date: 20.06.2002
Chapter 2 Demand Filed:    22.01.2003    
IPC:
A61K 38/00 (2006.01), A61K 39/00 (2006.01), C07K 14/72 (2006.01)
Applicants: GREENVILLE HOSPITAL SYSTEM [US/US]; 701 Grove Road, Greenville, SC 29605 (US) (For All Designated States Except US).
PRICE, Thomas, M. [US/US]; (US) (For US Only)
Inventors: PRICE, Thomas, M.; (US)
Agent: MULLINAX, J., Bennett; Dority & Manning, PA, PO Box 1449, Greenville, SC 29602-1449 (US)
Priority Data:
09/887,280 22.06.2001 US
Title (EN) MEMBRANE ASSOCIATED PROGESTERONE RECEPTOR
(FR) RECEPTEUR DE LA PROGESTERONE ASSOCIE A LA MEMBRANE
Abstract: front page image
(EN)The invention provides for human progesterone receptor proteins (PR-M and PR-H) and polynucleotides that identify and encode the proteins. The invention also provides expression factor, host cells, and methods for treating and preventing disorders associated with the expression or binding of the PR-M and/or PR-H receptors. The invention also provides for antibodies, agonists, and antagonists that have utility in the treatment of similar disorders.
(FR)L'invention concerne des protéines du récepteur de la progestérone humaine (PR-M and PR-H) et des polynucléotides qui identifient et codent ces protéines. L'invention concerne par ailleurs un facteur d'expression, des cellules hôtes et des méthodes de traitement et de prévention de troubles associés à l'expression ou à la liaison des récepteurs PR-M et/ou PR-H. De plus, l'invention concerne des anticorps, des agonistes et des antagonistes utilisés dans le traitement de troubles similaires.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)